Breakthrough Drug Doubles Survival Time for Pancreatic Cancer Patients
A pill named daraxonrasib has been found to nearly double the survival time for patients with advanced pancreatic cancer, with experts calling the clinical trial a game changer.
This drug represents a significant advancement in treating a disease known for having the highest mortality rate among major cancers.
Daraxonrasib works by targeting and inhibiting the mutated KRAS gene, which is present in over 90% of pancreatic tumors and drives cancer progression.
Clinical Trial Results
The trial involved 500 patients across North America, Europe, and Asia. It showed that patients receiving chemotherapy had an average survival time of 6.6 months, whereas those treated with daraxonrasib survived on average 13.2 months. Additionally, the drug was associated with fewer side effects.
"These results are landscape-changing for metastatic pancreatic cancer patients with a KRAS mutation," said Rachna Shroff, chief of the division of haematology/oncology at the University of Arizona Cancer Centre.
Challenges in Pancreatic Cancer Diagnosis and Mortality
Pancreatic cancer is often diagnosed at a late stage and is notoriously difficult to treat. More than half of patients diagnosed with pancreatic cancer die within three months.
In the UK, there are approximately 11,500 new cases annually, with around 10,200 deaths each year, according to Cancer Research UK. The disease claimed the life of actor Alan Rickman in 2016, who died five months after his diagnosis.
Common symptoms include jaundice, itchy skin, dark urine, pale stools, unexplained weight loss, fatigue, and fever.
Diagnosis is challenging because early-stage symptoms are often absent or nonspecific, frequently resembling other conditions.
Details of the Trial and Patient Outcomes
The trial, led by American researchers and presented at the American Society of Clinical Oncology annual meeting in Chicago, enrolled 500 patients: 248 received daraxonrasib and 252 received chemotherapy. Most participants had tumors with specific KRAS gene mutations.
Besides significantly extending survival, daraxonrasib, administered once daily, resulted in fewer severe side effects compared to chemotherapy.
Severe side effects occurred in 43.6% of patients on daraxonrasib versus 57.5% on chemotherapy.
Expert and Advocacy Group Reactions
Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, stated, "These treatments are some of the most exciting developments we have seen in pancreatic cancer for a very long time."
She added, "More time with those we love most is truly priceless. We must do everything possible to ensure the most promising new treatments are available here in the UK."
